Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esflurbiprofen Hydrogel Patch in Acute Soft Tissue Injuries
NCT04908748Phase 2Completed
- Sponsor
- Teikoku Seiyaku Co., Ltd.
- Start
- May 2021
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of esflurbiprofen in soft tissue injury, sprain, muscle strain and 1 more (2 arms), sponsored by Teikoku Seiyaku Co., Ltd. Primary endpoint: Change of Pain-on-movement (POM) Compared to Baseline at 72 hours. Started May 2021; status: completed.
02
Drugs
esflurbiprofen
03
Conditions
soft tissue injurysprainmuscle straincontusion
Beyond the preview
Go deeper on NCT04908748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04908748.